Literature DB >> 16684959

Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy.

H Joachim Deeg1, Margaret O'Donnell, Jakub Tolar, Rajni Agarwal, Richard E Harris, Stephen A Feig, Mary C Territo, Robert H Collins, Peter A McSweeney, Edward A Copelan, Shakila P Khan, Ann Woolfrey, Barry Storer.   

Abstract

In 87 patients with aplastic anemia who failed to respond to immunosuppressive treatment, we determined the minimal dose of total body irradiation (TBI) required when added to antithymocyte globulin (ATG, 30 mg/kg x 3) plus cyclophosphamide (CY, 50 mg/kg x 4) to achieve engraftment of unrelated donor marrow. TBI was started at 3 x 200 cGy, to be escalated or deescalated in steps of 200 cGy depending on graft failure or toxicity. Patients were aged 1.3 to 53.5 years (median, 18.6 years). The interval from diagnosis to transplantation was 3 to 328 months (median, 14.6 months). Donors were HLA-A, -B, -C, -DR, and -DQ identical for 62 patients, and nonidentical for 1 to 3 HLA loci at the antigen or allele level for 25. The dose-limiting toxicity was diffuse pulmonary injury. The optimum TBI dose was 1 x 200 cGy. Nine patients did not tolerate ATG and were prepared with CY + TBI. Graft failure occurred in 5% of patients. With a median follow-up of 7 years, 38 (61%) of 62 HLA-identical, and 10 (40%) of 25 HLA-nonidentical transplant recipients are surviving. The highest survival rate with HLA-identical transplants was observed at 200 cGy TBI. Thus, low-dose TBI + CY + ATG conditioning resulted in excellent outcome of unrelated transplants in patients with aplastic anemia who had received multiple transfusions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16684959      PMCID: PMC1895515          DOI: 10.1182/blood-2006-03-005041

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.

Authors:  H Joachim Deeg; Barry E Storer; Michael Boeckh; Paul J Martin; Jeannine S McCune; David Myerson; Shelly Heimfeld; Mary E Flowers; Claudio Anasetti; Kristine C Doney; John A Hansen; Hans-Peter Kiem; Richard A Nash; Paul V O'Donnell; Jerald P Radich; Brenda M Sandmaier; Bart L Scott; Mohamed L Sorror; E Houston Warren; Robert P Witherspoon; Ann Woolfrey; Frederick R Appelbaum; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2006-05       Impact factor: 5.742

2.  Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation.

Authors:  A Bacigalupo; R Oneto; B Bruno; G Socié; J Passweg; A Locasciulli; M T Van Lint; A Tichelli; S McCann; J Marsh; P Ljungman; J Hows; P Marin; H Schrezenmeier
Journal:  Acta Haematol       Date:  2000       Impact factor: 2.195

3.  Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia.

Authors:  Y Kodera; Y Morishima; S Kato; Y Akiyama; H Sao; T Matsuyama; K Kawa; H Sakamaki; S Nakagawa; N Hirabayashi; H Dohi; S Okamoto; A Hiraoka; H Gondo; M Tsuchida; H O; M Harada; S Asano; T Juji; T Sasazuki; F Takaku
Journal:  Bone Marrow Transplant       Date:  1999-11       Impact factor: 5.483

4.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

Authors:  P A McSweeney; D Niederwieser; J A Shizuru; B M Sandmaier; A J Molina; D G Maloney; T R Chauncey; T A Gooley; U Hegenbart; R A Nash; J Radich; J L Wagner; S Minor; F R Appelbaum; W I Bensinger; E Bryant; M E Flowers; G E Georges; F C Grumet; H P Kiem; B Torok-Storb; C Yu; K G Blume; R F Storb
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

5.  Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect.

Authors:  R W Childs; E Clave; J Tisdale; M Plante; N Hensel; J Barrett
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

Review 6.  Improving availability and safety of unrelated donor transplants.

Authors:  C Anasetti; E W Petersdorf; P J Martin; A Woolfrey; J A Hansen
Journal:  Curr Opin Oncol       Date:  2000-03       Impact factor: 3.645

7.  Long-term outcome after bone marrow transplantation for severe aplastic anemia.

Authors:  Lionel Ades; Jean-Yves Mary; Marie Robin; Christèle Ferry; Raphael Porcher; Hélène Esperou; Patricia Ribaud; Agnès Devergie; Richard Traineau; Eliane Gluckman; Gérard Socié
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

8.  Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.

Authors:  H Joachim Deeg; Barry Storer; John T Slattery; Claudio Anasetti; Kristine C Doney; John A Hansen; Hans-Peter Kiem; Paul J Martin; Effie Petersdorf; Jerald P Radich; Jean E Sanders; Howard M Shulman; Edus H Warren; Robert P Witherspoon; Eileen M Bryant; Thomas R Chauncey; Lisa Getzendaner; Rainer Storb; Frederick R Appelbaum
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

9.  Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients.

Authors:  H J Deeg; G Socié; G Schoch; M Henry-Amar; R P Witherspoon; A Devergie; K M Sullivan; E Gluckman; R Storb
Journal:  Blood       Date:  1996-01-01       Impact factor: 22.113

10.  HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.

Authors:  Michael B Maris; Dietger Niederwieser; Brenda M Sandmaier; Barry Storer; Monic Stuart; David Maloney; Effie Petersdorf; Peter McSweeney; Michael Pulsipher; Ann Woolfrey; Thomas Chauncey; Ed Agura; Shelly Heimfeld; John Slattery; Ute Hegenbart; Claudio Anasetti; Karl Blume; Rainer Storb
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

View more
  44 in total

Review 1.  How I treat acquired aplastic anemia.

Authors:  Phillip Scheinberg; Neal S Young
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

Review 2.  Alternative donor transplants for severe aplastic anemia.

Authors:  Andrea Bacigalupo
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  The diagnosis and treatment of aplastic anemia: a review.

Authors:  Maurizio Miano; Carlo Dufour
Journal:  Int J Hematol       Date:  2015-04-03       Impact factor: 2.490

4.  Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010.

Authors:  Michael A Pulsipher; Neal S Young; Jakub Tolar; Antonio M Risitano; H Joachim Deeg; Paolo Anderlini; Rodrigo Calado; Seiji Kojima; Mary Eapen; Richard Harris; Phillip Scheinberg; Sharon Savage; Jaroslaw P Maciejewski; Ramon V Tiu; Nancy DiFronzo; Mary M Horowitz; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-27       Impact factor: 5.742

Review 5.  Alternative donor transplant of benign primary hematologic disorders.

Authors:  J Tolar; P Sodani; H Symons
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

6.  Association between donor leukocyte telomere length and survival after unrelated allogeneic hematopoietic cell transplantation for severe aplastic anemia.

Authors:  Shahinaz M Gadalla; Tao Wang; Michael Haagenson; Stephen R Spellman; Stephanie J Lee; Kirsten M Williams; Jason Y Wong; Immaculata De Vivo; Sharon A Savage
Journal:  JAMA       Date:  2015-02-10       Impact factor: 56.272

Review 7.  Clinical management of aplastic anemia.

Authors:  Amy E Dezern; Robert A Brodsky
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

8.  Optimizing conditioning regimen with low-dose irradiation or busulfan enables the outcome of transplantation from a 6-7/8 HLA-matched donor comparable to that from an 8/8 HLA-matched unrelated donor in severe aplastic anemia patients under 40 years.

Authors:  Xia Qin; Yi-Ping Zhu; Cheng-Juan Luo; Ming Zhou; Ke Huang; Chun Chen; Wei-Ping Zhang; Yuan Sun; Rong-Mu Luo; Xiang-Feng Tang; Ting Yang; Xian-Min Song; Shao-Yan Hu; Zi-Min Sun; Jiong Hu; Shun-Qing Wang; Jing Chen
Journal:  Ann Hematol       Date:  2021-05-14       Impact factor: 3.673

9.  Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia.

Authors:  Michael J Eckrich; Kwang-Woo Ahn; Richard E Champlin; Peter Coccia; Kamar Godder; John Horan; David Margolis; H Joachim Deeg; Mary Eapen
Journal:  Am J Hematol       Date:  2013-11-15       Impact factor: 10.047

10.  A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.

Authors:  Shalini Shenoy; Mary Eapen; Julie A Panepinto; Brent R Logan; Juan Wu; Allistair Abraham; Joel Brochstein; Sonali Chaudhury; Kamar Godder; Ann E Haight; Kimberly A Kasow; Kathryn Leung; Martin Andreansky; Monica Bhatia; Jignesh Dalal; Hilary Haines; Jennifer Jaroscak; Hillard M Lazarus; John E Levine; Lakshmanan Krishnamurti; David Margolis; Gail C Megason; Lolie C Yu; Michael A Pulsipher; Iris Gersten; Nancy DiFronzo; Mary M Horowitz; Mark C Walters; Naynesh Kamani
Journal:  Blood       Date:  2016-09-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.